Mariano Ferraresso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8813688/publications.pdf

Version: 2024-02-01

72	968	471061	525886
papers	citations	17 h-index	27 g-index

72	72	72	1336
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Allograft Vesicoureteral Reflux after Kidney Transplantation. Medicina (Lithuania), 2022, 58, 81.	0.8	3
2	In Vitro Study Evaluating the Effect of Different Immunosuppressive Agents on Human Polyomavirus BK Replication. Transplantation Proceedings, 2022, 54, 2035-2041.	0.3	1
3	New-Onset Diabetes after Kidney Transplantation. Medicina (Lithuania), 2021, 57, 250.	0.8	32
4	Utility and safety of early allograft biopsy in adult deceased donor kidney transplant recipients. Clinical and Experimental Nephrology, 2020, 24, 356-368.	0.7	13
5	Viral Genomic Characterization and Replication Pattern of Human Polyomaviruses in Kidney Transplant Recipients. Viruses, 2020, 12, 1280.	1.5	10
6	COVID-19 and kidney transplantation: an Italian Survey and Consensus. Journal of Nephrology, 2020, 33, 667-680.	0.9	40
7	Treatment options for localised renal cell carcinoma of the transplanted kidney. World Journal of Transplantation, 2020, 10, 147-161.	0.6	4
8	Allograft artery mycotic aneurysm after kidney transplantation: A case report and review of literature. World Journal of Clinical Cases, 2020, 8, 912-921.	0.3	3
9	Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation. World Journal of Clinical Cases, 2019, 7, 270-290.	0.3	23
10	Microwave Ablation of Renal Cell Carcinoma of the Transplanted Kidney: Two Cases. CardioVascular and Interventional Radiology, 2019, 42, 1653-1657.	0.9	4
11	Pretransplant Single Antigen Beadâ€“Detected HLA Antibodies in Kidney Transplant Long-term Outcome: A Single-Center Cohort Experience. Transplantation Proceedings, 2019, 51, 707-714.	0.3	1
12	Characterization of an in vitro model to study the possible role of polyomavirus BK in prostate cancer. Journal of Cellular Physiology, 2019, 234, 11912-11922.	2.0	7
13	Systematic review of ablative therapy for the treatment of renal allograft neoplasms. World Journal of Clinical Cases, 2019, 7, 2487-2504.	0.3	16
14	Living-Donor Kidney Transplant in a Patient With Type B Mayer-Rokitansky-KÃ¼ster-Hauser Syndrome, Reconstructed Vagina, and Abnormal Pelvic Vessels: A Case Report. Experimental and Clinical Transplantation, 2019, 17, 266-268.	0.2	0
15	Impact of Donor Age on Clinical Outcomes of Primary Single Kidney Transplantation From Maastricht Category-III Donors After Circulatory Death. Transplantation Direct, 2018, 4, e396.	0.8	18
16	Intra-operative Postperfusion Micronephrolithotomy for Renal Allograft Lithiasis: A Case Report. Transplantation Proceedings, 2018, 50, 3950-3953.	0.3	3
17	PERCUTANEOUS APPROACH TO COMPLEX RENAL ARTERY STENOSES IN PEDIATRIC RENOVASCULAR HYPERTENSION. Journal of Hypertension, 2018, 36, e155.	0.3	0
18	Multidisciplinary management of complicated bilateral renal artery aneurysm in a woman of childbearing age. Journal of Surgical Case Reports, 2018, 2018, rjy147.	0.2	3

#	Article	IF	Citations
19	Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience. Transplantation Proceedings, 2017, 49, 1766-1772.	0.3	6
20	Re: Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. European Urology, 2016, 70, 401.	0.9	0
21	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood, 2016, 127, 365-367.	0.6	67
22	ADPKD: clinical issues before and after renal transplantation. Journal of Nephrology, 2016, 29, 755-763.	0.9	2
23	A Two-Year Experience with a Rapid Access, Self-Sealing, Polycarbonate Urethane Nanofiber Vascular access Graft for Hemodialysis. Journal of Vascular Access, 2016, 17, 210-214.	0.5	15
24	Human herpesvirus-6 and polyomaviruses DNAemia in children and young adult patients after kidney transplantation. Future Virology, 2015, 10, 1275-1284.	0.9	2
25	Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. Pharmacogenomics, 2015, 16, 483-491.	0.6	5
26	High frequency of Merkel cell polyomavirus DNA in the urine of kidney transplant recipients and healthy controls. Journal of Clinical Virology, 2014, 61, 565-570.	1.6	33
27	Threeâ€yr safety and efficacy of everolimus and lowâ€dose cyclosporine in de novo pediatric kidney transplant patients. Pediatric Transplantation, 2014, 18, 350-356.	0.5	18
28	Endograft infection following emergency repair for abdominal aortic aneurysm dissection and the undervalued role of the bowel reservoir. Surgical Practice, 2013, 17, 31-33.	0.1	0
29	Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients. Pharmacogenomics, 2013, 14, 1605-1613.	0.6	13
30	A Review on JC Virus Infection in Kidney Transplant Recipients. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	54
31	Early Experience with a Newly Developed Electrospun Polycarbonate-urethane Vascular Graft for Hemodialysis Access. Journal of Vascular Access, 2013, 14, 252-256.	0.5	16
32	Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab. Journal of Medical Virology, 2012, 84, 1464-1470.	2.5	19
33	The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Pediatric Transplantation, 2012, 16, 658-663.	0.5	13
34	Search for Genomic Sequences of Microbial Agents in Atherosclerotic Plaques. International Journal of Immunopathology and Pharmacology, 2011, 24, 243-246.	1.0	10
35	Association Between CYP3A5 Polymorphisms and Blood Pressure in Kidney Transplant Recipients Receiving Calcineurin Inhibitors. Clinical and Experimental Hypertension, 2011, 33, 359-365.	0.5	14
36	Successful medical treatment of EBV smooth muscle tumor in a renal transplant recipient. Pediatric Transplantation, 2010, 14, E101-E104.	0.5	17

#	Article	IF	Citations
37	Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacological Reports, 2010, 62, 1159-1169.	1.5	44
38	Longitudinal evaluation of mycophenolic acid pharmacokinetics in pediatric kidney transplant recipients. The role of postâ€transplant clinical and therapeutic variables. Clinical Transplantation, 2009, 23, 264-270.	0.8	17
39	Pediatric Kidney Transplantation: A Snapshot 10 Years Later. Transplantation Proceedings, 2008, 40, 1852-1853.	0.3	7
40	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. Transplantation, 2008, 86, 1445-1451.	0.5	24
41	The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. Medical Science Monitor, 2008, 14, CR251-254.	0.5	15
42	Combined liver-kidney transplantation in glycogen storage disease Ia: A case beyond the guidelines. Liver Transplantation, 2007, 13, 762-764.	1.3	23
43	Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatric Transplantation, 2007, 11, 296-300.	0.5	60
44	Pharmacokinetic of Cyclosporine Microemulsion in Pediatric Kidney Recipients Receiving A Quadruple Immunosuppressive Regimen: The Value of C2 Blood Levels. Transplantation, 2005, 79, 1164-1168.	0.5	17
45	C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: Is there any threat for chronic rejection development?. Pediatric Transplantation, 2005, 9, 328-331.	0.5	4
46	One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transplant International, 2005, 18, 36-42.	0.8	19
47	Heterotopic cardiac xenotransplantation in rodents: Report of a refined technique in a hamster-to-rat model. Microsurgery, 2005, 25, 227-234.	0.6	14
48	Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient. Pediatric Nephrology, 2005, 20, 1186-1188.	0.9	40
49	Mycophenolate Mofetil Pharmacokinetic Monitoring in Pediatric Kidney Transplant Recipients. Transplantation Proceedings, 2005, 37, 856-858.	0.3	10
50	Nosocomial Infection in Kidney Transplant Recipients: A Retrospective Analysis of a Single-Center Experience. Transplantation Proceedings, 2005, 37, 2495-2496.	0.3	16
51	Value of Intraoperative Resistive Index in Kidney Transplant. Transplantation Proceedings, 2005, 37, 2472-2473.	0.3	9
52	Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination. Transplantation Proceedings, 2004, 36, 685-686.	0.3	6
53	Conversion from tacrolimus to cyclosporine for a nonâ€“dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report. Transplantation Proceedings, 2004, 36, 1332-1335.	0.3	5
54	C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients. Transplantation Proceedings, 2004, 36, 2656-2658.	0.3	3

#	Article	IF	Citations
55	Carbon dioxide as a valuable contrast agent for identifying iatrogenic arteriovenous fistulas in transplanted kidneys. Nephrology Dialysis Transplantation, 2003, 18, 2189-2192.	0.4	2
56	Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients. Pediatric Nephrology, 2002, 17, 664-667.	0.9	9
57	Carbon dioxide subtraction angiography for management of kidney transplant vascular complications. Transplantation Proceedings, 2001, 33, 3388-3389.	0.3	2
58	Conversion from cyclosporine to tacrolimus for refractory acute rejection in pediatric kidney transplant recipients: a single-center experience. Transplantation Proceedings, 2001, 33, 3590-3591.	0.3	1
59	Kidneys from border-age donors in the cyclosporine era: long-term function and outcome. Transplantation Proceedings, 1999, 31, 294-295.	0.3	3
60	Use of a newly developed ultrasound contrast medium for color doppler evaluation in kidney transplantation. Transplantation Proceedings, 1999, 31, 1354-1356.	0.3	5
61	ANALYSIS OF BLOOD FLOW DISTRIBUTION IN KIDNEY TRANSPLANTS UNDER 3 DIFFERENT IMMUNOSUPPRESSIVE REGIMENS. Transplantation, 1999, 67, S13.	0.5	0
62	Twenty-six year surgical experience of 259 pediatric transplants in 235 children and long-term follow-up of 181 under cyclosporine therapy. Transplantation Proceedings, 1998, 30, 1977-1979.	0.3	1
63	Long-term function and survival rates of kidneys from extreme-age donors in the cyclosporine era. Transplantation Proceedings, 1998, 30, 2274-2275.	0.3	5
64	Protective effect of L-arginine on liver ischemia-reperfusion injury. Transplantation Proceedings, 1997, 29, 393-394.	0.3	13
65	Neoral versus sandimmun in kidney-pancreas transplantation. Transplantation Proceedings, 1997, 29, 2924-2926.	0.3	10
66	Effect of l-arginine and oligotide on liver ischemia-reperfusion injury. Transplantation Proceedings, 1997, 29, 2992-2993.	0.3	9
67	The protective effects ofL-arginine after liver ischaemia/reperfusion injury in a pig model. , 1997, 183, 477-485.		31
68	New immunosuppressive agents for pediatric transplantation. Pediatric Nephrology, 1993, 7, 567-573.	0.9	4
69	IMMUNOSUPPRESSIVE EFFECTS OF DEFIBROTIDE. Transplantation, 1993, 56, 928-933.	0.5	17
70	THE MECHANISM OF UNRESPONSIVENESS TO ALLOGRAFTS INDUCED BY RAPAMYCIN AND RAPAMYCIN/CYCLOSPORINE TREATMENT IN RATS. Transplantation, 1993, 55, 888-893.	0.5	19
71	EVIDENCE THAT RAPAMYCIN RESCUE THERAPY DELAYS REJECTION OF MAJOR (MHC) PLUS MINOR (NON-MHC) HISTOINCOMPATIBLE HEART ALLOGRAFTS IN RATS. Transplantation, 1992, 54, 704-709.	0.5	17
72	Effects of Defibrotide on Renal Function and Urinary Prostanoid Excretion in Ciclosporin-Treated Rats. Nephron, 1991, 59, 477-481.	0.9	2